Carlo Visco, MD

home / authors / carlo-visco,-md

Articles

Carlo Visco, MD, of the University of Verona

Dr. Visco on Results from the MANTLE-FIRST Study in Relapsed/Refractory MCL

Carlo Visco, MD
October 15th 2020

Carlo Visco, MD, discusses the results of early relapse versus late relapse in the MANTLE-FIRST study with ibrutinib versus chemoimmunotherapy in mantle cell lymphoma.

Read More

Dr. Visco on Next Steps for the MANTLE-FIRST Trial in Relapsed/Refractory MCL

Dr. Visco on Next Steps for the MANTLE-FIRST Trial in Relapsed/Refractory MCL

Carlo Visco, MD
September 17th 2020

Carlo Visco, MD, discusses the next steps for the international, retrospective MANTLE-FIRST trial in patients with relapsed/refractory mantle cell lymphoma.

Read More

Dr. Visco on the Utility of Bendamustine in MCL

Dr. Visco on the Utility of Bendamustine in MCL

Carlo Visco, MD
September 15th 2020

Carlo Visco, MD, discusses the utility of bendamustine-based regimens in mantle cell lymphoma.

Read More

Dr. Visco on the Utility of Cytarabine in MCL

Dr. Visco on the Utility of Cytarabine in MCL

Carlo Visco, MD
September 10th 2020

Carlo Visco, MD, discusses the utility of cytarabine in relapsed/refractory mantle cell lymphoma.

Read More

Dr. Visco on the Rationale for the MANTLE-FIRST Trial in R/R MCL

Dr. Visco on the Rationale for the MANTLE-FIRST Trial in R/R MCL

Carlo Visco, MD
September 9th 2020

Carlo Visco, MD, discusses the rationale for the international, retrospective MANTLE-FIRST trial in relapsed/refractory mantle cell lymphoma.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need